Skip to main content

Drug Interactions between Decaject and futibatinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexAMETHasone futibatinib

Applies to: Decaject (dexamethasone) and futibatinib

MONITOR: Coadministration with inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may decrease the plasma concentrations of futibatinib, which is a substrate of both the isoenzyme and the efflux transporter. Drug interaction studies have shown that single dose administration of futibatinib with multiple doses of rifampin, a combined P-gp and potent CYP450 3A4 inducer, decreased futibatinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 53% and 64%, respectively, compared to futibatinib alone. Reduced efficacy of futibatinib may occur. The interaction has not been studied with other, less potent dual inducers of CYP450 3A4 and P-gp.

MANAGEMENT: The potential for diminished pharmacologic effects of futibatinib should be considered during coadministration with dual CYP450 3A4 and P-gp inducers. Alternative treatments may be required if an interaction is suspected.

References

  1. (2022) "Product Information. Lytgobi (futibatinib)." Taiho Oncology, Inc., 1

Switch to consumer interaction data

Drug and food interactions

Major

futibatinib food

Applies to: futibatinib

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of futibatinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to futibatinib may increase the risk of adverse effects such as retinal pigment epithelial detachment, dry eye/corneal keratitis, pyrexia, hyperphosphatemia and soft tissue mineralization, palmar-plantar erythrodysesthesia syndrome, fatigue, nail toxicity, urinary tract infection, constipation, diarrhea, dry mouth, increased liver function tests (ALT and AST), stomatitis, abdominal pain, ascites, bile duct obstruction, and musculoskeletal pain.

MANAGEMENT: Patients should be advised to avoid consumption of grapefruit or grapefruit juice during treatment with futibatinib.

References

  1. (2022) "Product Information. Lytgobi (futibatinib)." Taiho Oncology, Inc., 1

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer